Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Auderghem – page 133

1 992 clinical trials in Auderghem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Auderghem at a glance
1 992
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 992 trials in Auderghem

Open in trial search

Pneumonia

Not recruiting

Study on the Effects of Amikacin Liposome Inhalation, Azithromycin, and Ethambutol in Adults with Newly Diagnosed Nontuberculous Mycobacterial Lung Infection

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin
  • Sponsor:Insmed Inc.

Study on the Safety and Effectiveness of Epcoritamab, Venetoclax, and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Genmab A/S

Hidradenitis

Not recruiting

Study on the Long-Term Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Study on the Safety and Effectiveness of Tovinontrine for Adults with Chronic Heart Failure with Reduced Ejection Fraction

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tovinontrine
  • Sponsor:Cardurion Pharmaceuticals Inc.

Study Comparing Selpercatinib with a Drug Combination for Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Study on the Effects of Itepekimab on Airway Inflammation in Former Smokers with Chronic Obstructive Pulmonary Disease (COPD)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Anal cancer recurrent

Not recruiting

Study of Retifanlimab, Carboplatin, and Paclitaxel for Patients with Inoperable or Metastatic Anal Canal Squamous Cell Carcinoma Not Treated with Chemotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Incyte Corp.

Breast cancer

Not recruiting

Study of Trastuzumab Deruxtecan with or without Pertuzumab for Patients with HER2-positive Metastatic Breast Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AstraZeneca AB

Lupus nephritis

Not recruiting

Study on Anifrolumab for Adults with Active Lupus Nephritis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Neoplasm malignant+3

Not recruiting

Study of ALX148, Pembrolizumab, and Chemotherapy for Patients with Advanced Head and Neck Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Evorpacept
  • Sponsor:Alx Oncology Holdings Inc.

Breast cancer

Not recruiting

Study of Fulvestrant and Abemaciclib for Women with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Parkinson's disease

Not recruiting

Study on the Effectiveness and Safety of ND0612 Infusion vs. Oral Treatment for Parkinson's Disease Patients with Motor Fluctuations

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carbidopa
  • Sponsor:Neuroderm Ltd.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Auderghem

What the registry says about research in the country

01 Neoplasms

In Auderghem, researchers are concentrating on lung cancer, specifically Non‑Small Cell Lung Cancer and small cell lung cancer. The two active studies compare new immune‑targeted agents such as pumitamig and obrixtamig against established therapies like pembrolizumab and standard chemotherapy, aiming to improve overall survival and disease control.

  • Comparative efficacy of novel immunotherapies
  • Evaluation of survival benefit in advanced disease
  • Biomarker‑guided patient selection (e.g., DLL3 expression)
  • Combination regimens with checkpoint inhibitors

Both trials are actively recruiting, reflecting a growing commitment in Auderghem to advance treatment options for patients with aggressive lung cancers.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.